mr DEAN PARANICAS

Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407).

Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407).

Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407).

Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407).

Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407).

Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407).

Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407).

Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407).

Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407).

Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407).

Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691). Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 7174). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283). Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407).

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA comments with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Opposing the SMART Act (S. 1246).

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283).

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246).

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA comments with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Opposing the SMART Act (S. 1246).

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283).

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246).

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246).

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA comments with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Opposing the SMART Act (S. 1246).

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283).

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283).

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA comments with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Opposing the SMART Act (S. 1246).

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246).

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283).

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA comments with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Opposing the SMART Act (S. 1246).

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246).

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283).

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283).

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283).

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246).

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283).

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA comments with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Opposing the SMART Act (S. 1246).

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283).

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA comments with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Opposing the SMART Act (S. 1246).

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246).

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246).

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283).

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA comments with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Opposing the SMART Act (S. 1246).

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283).

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246).

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503 and S. 2916). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing WHO TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Submitted comments to CMS concerning Transitional Coverage for Emerging Technologies (TCET) pathway. Opposing the SMART Act (S. 1246). Supporting the ORPHAN CURES Act (H.R. 5539). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391/S. 2764). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283).

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing legislation regarding health care costs. Opposing various legislative efforts to relocate supply and logistics chains. Opposing various legislative and executive efforts to impose an international price index. Supporting the DISARM Act (H.R. 4127). Supporting the PASTEUR Act (S. 2076 and H.R. 3932). Supporting the modernization of prescribing information to allow digital in lieu of printed information. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting CMS proposed rule on Medicare Coverage of Innovative Technology (MCIT). Engaging various components of the Build Back Better Act.

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing legislation regarding health care costs. Opposing various legislative efforts to relocate supply and logistics chains. Opposing various legislative and executive efforts to impose an international price index. Supporting the DISARM Act (H.R. 4127). Supporting the PASTEUR Act (S. 2076 and H.R. 3932). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 7559). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting CMS proposed rule on Medicare Coverage of Innovative Technology (MCIT). Engaging various components of the Build Back Better Act. Opposing CMS reimbursement for combined diagnostics test. Opposing TRIPS waiver. Supporting PDUFA and MDUFA passage. Commenting on risk management to mitigate drug shortages. Supporting the extension of the SBIR program. Supporting H.R. 8188, the Saving Access to Laboratory Services Act (SALSA). Supporting H.R. 4346, the Creating Helpful Incentives to Produce Semiconductors (CHIPS) Act. Opposing the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing legislation regarding health care costs. Opposing various legislative efforts to relocate supply and logistics chains. Opposing various legislative and executive efforts to impose an international price index. Supporting the DISARM Act (H.R. 4127). Supporting the PASTEUR Act (S. 2076 and H.R. 3932). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 7559). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting CMS proposed rule on Medicare Coverage of Innovative Technology (MCIT). Engaging various components of the Build Back Better Act. Opposing CMS reimbursement for combined diagnostics test. Opposing TRIPS waiver. Supporting PDUFA and MDUFA passage.

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing legislation regarding health care costs. Opposing various legislative efforts to relocate supply and logistics chains. Opposing various legislative and executive efforts to impose an international price index. Supporting the DISARM Act (H.R. 4127). Supporting the PASTEUR Act (S. 2076 and H.R. 3932). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 7559). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting CMS proposed rule on Medicare Coverage of Innovative Technology (MCIT). Engaging various components of the Build Back Better Act. Opposing CMS reimbursement for combined diagnostics test. Opposing TRIPS waiver. Supporting PDUFA and MDUFA passage. Commenting on risk management to mitigate drug shortages. Supporting the extension of the SBIR program. Supporting H.R. 8188, the Saving Access to Laboratory Services Act (SALSA). Supporting H.R. 4346, the Creating Helpful Incentives to Produce Semiconductors (CHIPS) Act. Opposing the Inflation Reduction Act.

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing legislation regarding health care costs. Opposing various legislative efforts to relocate supply and logistics chains. Opposing various legislative and executive efforts to impose an international price index. Supporting the DISARM Act (H.R. 4127). Supporting the PASTEUR Act (S. 2076 and H.R. 3932). Supporting the modernization of prescribing information to allow digital in lieu of printed information. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting CMS proposed rule on Medicare Coverage of Innovative Technology (MCIT). Engaging various components of the Build Back Better Act.

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing legislation regarding health care costs. Opposing various legislative efforts to relocate supply and logistics chains. Opposing various legislative and executive efforts to impose an international price index. Supporting the DISARM Act (H.R. 4127). Supporting the PASTEUR Act (S. 2076 and H.R. 3932). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 7559). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting CMS proposed rule on Medicare Coverage of Innovative Technology (MCIT). Engaging various components of the Build Back Better Act. Opposing CMS reimbursement for combined diagnostics test. Opposing TRIPS waiver. Supporting PDUFA and MDUFA passage.

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing legislation regarding health care costs. Opposing various legislative efforts to relocate supply and logistics chains. Opposing various legislative and executive efforts to impose an international price index. Supporting the DISARM Act (H.R. 4127). Supporting the PASTEUR Act (S. 2076 and H.R. 3932). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 7559). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting CMS proposed rule on Medicare Coverage of Innovative Technology (MCIT). Engaging various components of the Build Back Better Act. Opposing CMS reimbursement for combined diagnostics test. Opposing TRIPS waiver. Supporting PDUFA and MDUFA passage. Commenting on risk management to mitigate drug shortages. Supporting the extension of the SBIR program. Supporting H.R. 8188, the Saving Access to Laboratory Services Act (SALSA). Supporting H.R. 4346, the Creating Helpful Incentives to Produce Semiconductors (CHIPS) Act. Opposing the Inflation Reduction Act.

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing legislation regarding health care costs. Opposing various legislative efforts to relocate supply and logistics chains. Opposing various legislative and executive efforts to impose an international price index. Supporting the DISARM Act (H.R. 4127). Supporting the PASTEUR Act (S. 2076 and H.R. 3932). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 7559). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting CMS proposed rule on Medicare Coverage of Innovative Technology (MCIT). Engaging various components of the Build Back Better Act. Opposing CMS reimbursement for combined diagnostics test. Opposing TRIPS waiver. Supporting PDUFA and MDUFA passage. Commenting on risk management to mitigate drug shortages. Supporting the extension of the SBIR program. Supporting H.R. 8188, the Saving Access to Laboratory Services Act (SALSA). Supporting H.R. 4346, the Creating Helpful Incentives to Produce Semiconductors (CHIPS) Act. Opposing the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing legislation regarding health care costs. Opposing various legislative efforts to relocate supply and logistics chains. Opposing various legislative and executive efforts to impose an international price index. Supporting the DISARM Act (H.R. 4127). Supporting the PASTEUR Act (S. 2076 and H.R. 3932). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 7559). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting CMS proposed rule on Medicare Coverage of Innovative Technology (MCIT). Engaging various components of the Build Back Better Act. Opposing CMS reimbursement for combined diagnostics test. Opposing TRIPS waiver. Supporting PDUFA and MDUFA passage. Commenting on risk management to mitigate drug shortages. Supporting the extension of the SBIR program. Supporting H.R. 8188, the Saving Access to Laboratory Services Act (SALSA). Supporting H.R. 4346, the Creating Helpful Incentives to Produce Semiconductors (CHIPS) Act. Opposing the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing legislation regarding health care costs. Opposing various legislative efforts to relocate supply and logistics chains. Opposing various legislative and executive efforts to impose an international price index. Supporting the DISARM Act (H.R. 4127). Supporting the PASTEUR Act (S. 2076 and H.R. 3932). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 7559). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting CMS proposed rule on Medicare Coverage of Innovative Technology (MCIT). Engaging various components of the Build Back Better Act. Opposing CMS reimbursement for combined diagnostics test. Opposing TRIPS waiver. Supporting PDUFA and MDUFA passage. Commenting on risk management to mitigate drug shortages. Supporting the extension of the SBIR program. Supporting H.R. 8188, the Saving Access to Laboratory Services Act (SALSA). Supporting H.R. 4346, the Creating Helpful Incentives to Produce Semiconductors (CHIPS) Act. Opposing the Inflation Reduction Act.

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing legislation regarding health care costs. Opposing various legislative efforts to relocate supply and logistics chains. Opposing various legislative and executive efforts to impose an international price index. Supporting the DISARM Act (H.R. 4127). Supporting the PASTEUR Act (S. 2076 and H.R. 3932). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 7559). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting CMS proposed rule on Medicare Coverage of Innovative Technology (MCIT). Engaging various components of the Build Back Better Act. Opposing CMS reimbursement for combined diagnostics test. Opposing TRIPS waiver. Supporting PDUFA and MDUFA passage.

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing legislation regarding health care costs. Opposing various legislative efforts to relocate supply and logistics chains. Opposing various legislative and executive efforts to impose an international price index. Supporting the DISARM Act (H.R. 4127). Supporting the PASTEUR Act (S. 2076 and H.R. 3932). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 7559). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting CMS proposed rule on Medicare Coverage of Innovative Technology (MCIT). Engaging various components of the Build Back Better Act. Opposing CMS reimbursement for combined diagnostics test. Opposing TRIPS waiver. Supporting PDUFA and MDUFA passage. Commenting on risk management to mitigate drug shortages. Supporting the extension of the SBIR program. Supporting H.R. 8188, the Saving Access to Laboratory Services Act (SALSA). Supporting H.R. 4346, the Creating Helpful Incentives to Produce Semiconductors (CHIPS) Act. Opposing the Inflation Reduction Act.

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing legislation regarding health care costs. Opposing various legislative efforts to relocate supply and logistics chains. Opposing various legislative and executive efforts to impose an international price index. Supporting the DISARM Act (H.R. 4127). Supporting the PASTEUR Act (S. 2076 and H.R. 3932). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 7559). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting CMS proposed rule on Medicare Coverage of Innovative Technology (MCIT). Engaging various components of the Build Back Better Act. Opposing CMS reimbursement for combined diagnostics test. Opposing TRIPS waiver. Supporting PDUFA and MDUFA passage. Commenting on risk management to mitigate drug shortages. Supporting the extension of the SBIR program. Supporting H.R. 8188, the Saving Access to Laboratory Services Act (SALSA). Supporting H.R. 4346, the Creating Helpful Incentives to Produce Semiconductors (CHIPS) Act. Opposing the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing legislation regarding health care costs. Opposing various legislative efforts to relocate supply and logistics chains. Opposing various legislative and executive efforts to impose an international price index. Supporting the DISARM Act (H.R. 4127). Supporting the PASTEUR Act (S. 2076 and H.R. 3932). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 7559). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting CMS proposed rule on Medicare Coverage of Innovative Technology (MCIT). Engaging various components of the Build Back Better Act. Opposing CMS reimbursement for combined diagnostics test. Opposing TRIPS waiver. Supporting PDUFA and MDUFA passage. Commenting on risk management to mitigate drug shortages. Supporting the extension of the SBIR program. Supporting H.R. 8188, the Saving Access to Laboratory Services Act (SALSA). Supporting H.R. 4346, the Creating Helpful Incentives to Produce Semiconductors (CHIPS) Act. Opposing the Inflation Reduction Act.

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing legislation regarding health care costs. Opposing various legislative efforts to relocate supply and logistics chains. Opposing various legislative and executive efforts to impose an international price index. Supporting the DISARM Act (H.R. 4127). Supporting the PASTEUR Act (S. 2076 and H.R. 3932). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 7559). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting CMS proposed rule on Medicare Coverage of Innovative Technology (MCIT). Engaging various components of the Build Back Better Act. Opposing CMS reimbursement for combined diagnostics test. Opposing TRIPS waiver. Supporting PDUFA and MDUFA passage. Commenting on risk management to mitigate drug shortages. Supporting the extension of the SBIR program. Supporting H.R. 8188, the Saving Access to Laboratory Services Act (SALSA). Supporting H.R. 4346, the Creating Helpful Incentives to Produce Semiconductors (CHIPS) Act. Opposing the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing legislation regarding health care costs. Opposing various legislative efforts to relocate supply and logistics chains. Opposing various legislative and executive efforts to impose an international price index. Supporting the DISARM Act (H.R. 4127). Supporting the PASTEUR Act (S. 2076 and H.R. 3932). Supporting the modernization of prescribing information to allow digital in lieu of printed information. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting CMS proposed rule on Medicare Coverage of Innovative Technology (MCIT). Engaging various components of the Build Back Better Act.

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing legislation regarding health care costs. Opposing various legislative efforts to relocate supply and logistics chains. Opposing various legislative and executive efforts to impose an international price index. Supporting the DISARM Act (H.R. 4127). Supporting the PASTEUR Act (S. 2076 and H.R. 3932). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 7559). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting CMS proposed rule on Medicare Coverage of Innovative Technology (MCIT). Engaging various components of the Build Back Better Act. Opposing CMS reimbursement for combined diagnostics test. Opposing TRIPS waiver. Supporting PDUFA and MDUFA passage. Commenting on risk management to mitigate drug shortages. Supporting the extension of the SBIR program. Supporting H.R. 8188, the Saving Access to Laboratory Services Act (SALSA). Supporting H.R. 4346, the Creating Helpful Incentives to Produce Semiconductors (CHIPS) Act. Opposing the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing legislation regarding health care costs. Opposing various legislative efforts to relocate supply and logistics chains. Opposing various legislative and executive efforts to impose an international price index. Supporting the DISARM Act (H.R. 4127). Supporting the PASTEUR Act (S. 2076 and H.R. 3932). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 7559). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting CMS proposed rule on Medicare Coverage of Innovative Technology (MCIT). Engaging various components of the Build Back Better Act. Opposing CMS reimbursement for combined diagnostics test. Opposing TRIPS waiver. Supporting PDUFA and MDUFA passage. Commenting on risk management to mitigate drug shortages. Supporting the extension of the SBIR program. Supporting H.R. 8188, the Saving Access to Laboratory Services Act (SALSA). Supporting H.R. 4346, the Creating Helpful Incentives to Produce Semiconductors (CHIPS) Act. Opposing the Inflation Reduction Act.

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing legislation regarding health care costs. Opposing various legislative efforts to relocate supply and logistics chains. Opposing various legislative and executive efforts to impose an international price index. Supporting the DISARM Act (H.R. 4127). Supporting the PASTEUR Act (S. 2076 and H.R. 3932). Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 7559). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting CMS proposed rule on Medicare Coverage of Innovative Technology (MCIT). Engaging various components of the Build Back Better Act. Opposing CMS reimbursement for combined diagnostics test. Opposing TRIPS waiver. Supporting PDUFA and MDUFA passage.

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing H.R. 3 legislation regarding health care costs. Opposing various legislative efforts to relocate supply and logistics chains. Opposing various legislative and executive efforts to impose an international price index. Supporting the DISARM Act (S. 1712 and H.R. 4100 in the previous Congress; yet to be reintroduced). Supporting the PASTEUR Act (S. 4760 and H.R. 8920 in the previous Congress; yet to be reintroduced). Supporting the modernization of prescribing information to allow digital in lieu of printed information. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting CMS proposed rule on Medicare Coverage of Innovative Technology (MCIT).

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing H.R. 3 legislation regarding health care costs. Opposing various legislative efforts to relocate supply and logistics chains. Opposing various legislative and executive efforts to impose an international price index. Supporting the DISARM Act (H.R. 4127). Supporting the PASTEUR Act (S. 2076 and H.R. 3932). Supporting the modernization of prescribing information to allow digital in lieu of printed information. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting CMS proposed rule on Medicare Coverage of Innovative Technology (MCIT).

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing H.R. 3 legislation regarding health care costs. Opposing various legislative efforts to relocate supply and logistics chains. Opposing various legislative and executive efforts to impose an international price index. Supporting the DISARM Act (S. 1712 and H.R. 4100 in the previous Congress; yet to be reintroduced). Supporting the PASTEUR Act (S. 4760 and H.R. 8920 in the previous Congress; yet to be reintroduced). Supporting the modernization of prescribing information to allow digital in lieu of printed information. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting CMS proposed rule on Medicare Coverage of Innovative Technology (MCIT).

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing H.R. 3 legislation regarding health care costs. Opposing various legislative efforts to relocate supply and logistics chains. Opposing various legislative and executive efforts to impose an international price index. Supporting the DISARM Act (H.R. 4127). Supporting the PASTEUR Act (S. 2076 and H.R. 3932). Supporting the modernization of prescribing information to allow digital in lieu of printed information. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting CMS proposed rule on Medicare Coverage of Innovative Technology (MCIT). Engaging various components of the Build Back Better Act.

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing H.R. 3 legislation regarding health care costs. Opposing various legislative efforts to relocate supply and logistics chains. Opposing various legislative and executive efforts to impose an international price index. Supporting the DISARM Act (S. 1712 and H.R. 4100 in the previous Congress; yet to be reintroduced). Supporting the PASTEUR Act (S. 4760 and H.R. 8920 in the previous Congress; reintroduced in June, not yet assigned bill numbers). Supporting the modernization of prescribing information to allow digital in lieu of printed information. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting CMS proposed rule on Medicare Coverage of Innovative Technology (MCIT).

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing H.R. 3 legislation regarding health care costs. Opposing various legislative efforts to relocate supply and logistics chains. Opposing various legislative and executive efforts to impose an international price index. Supporting the DISARM Act (H.R. 4127). Supporting the PASTEUR Act (S. 2076 and H.R. 3932). Supporting the modernization of prescribing information to allow digital in lieu of printed information. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting CMS proposed rule on Medicare Coverage of Innovative Technology (MCIT).

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing H.R. 3 legislation regarding health care costs. Opposing various legislative efforts to relocate supply and logistics chains. Opposing various legislative and executive efforts to impose an international price index. Supporting the DISARM Act (H.R. 4127). Supporting the PASTEUR Act (S. 2076 and H.R. 3932). Supporting the modernization of prescribing information to allow digital in lieu of printed information. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting CMS proposed rule on Medicare Coverage of Innovative Technology (MCIT). Engaging various components of the Build Back Better Act.

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing H.R. 3 legislation regarding health care costs. Opposing various legislative efforts to relocate supply and logistics chains. Opposing various legislative and executive efforts to impose an international price index. Supporting the DISARM Act (H.R. 4127). Supporting the PASTEUR Act (S. 2076 and H.R. 3932). Supporting the modernization of prescribing information to allow digital in lieu of printed information. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting CMS proposed rule on Medicare Coverage of Innovative Technology (MCIT). Engaging various components of the Build Back Better Act.

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing H.R. 3 legislation regarding health care costs. Opposing various legislative efforts to relocate supply and logistics chains. Opposing various legislative and executive efforts to impose an international price index. Supporting the DISARM Act (H.R. 4127). Supporting the PASTEUR Act (S. 2076 and H.R. 3932). Supporting the modernization of prescribing information to allow digital in lieu of printed information. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting CMS proposed rule on Medicare Coverage of Innovative Technology (MCIT).

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing H.R. 3 legislation regarding health care costs. Opposing various legislative efforts to relocate supply and logistics chains. Opposing various legislative and executive efforts to impose an international price index. Supporting the DISARM Act (H.R. 4127). Supporting the PASTEUR Act (S. 2076 and H.R. 3932). Supporting the modernization of prescribing information to allow digital in lieu of printed information. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting CMS proposed rule on Medicare Coverage of Innovative Technology (MCIT). Engaging various components of the Build Back Better Act.

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing H.R. 3 legislation regarding health care costs. Opposing various legislative efforts to relocate supply and logistics chains. Opposing various legislative and executive efforts to impose an international price index. Supporting the DISARM Act (H.R. 4127). Supporting the PASTEUR Act (S. 2076 and H.R. 3932). Supporting the modernization of prescribing information to allow digital in lieu of printed information. Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting CMS proposed rule on Medicare Coverage of Innovative Technology (MCIT).

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Supporting changes to Medicare Part D's coverage gap liability assignment and out-of-pocket cliff. Supporting changes to the America Invents Act to prevent double jeopardy of patent challenges under the inter partes review process. Supporting the Hatch Waxman Integrity Act (HR 990, S344). Opposing the Medicare Negotiations and Competitive Pricing Act (HR 1046). Generally supporting the proposed CMS Safe Harbor rule. Opposing H.R. 3 legislation regarding health care costs Opposing the FDA's Proposed Rule regarding the importation of prescription drugs (Docket No. FDA-2019-N-5711) Supporting H.R. 5741, the "Strengthening Innovation in Medicare and Medicaid Act Supporting the CMS Notice of Benefit and Payment Parameters (NBPP) Proposed Rule (CMS-9944-P) Opposing a proposed White House Executive Order concerning the Buy America Act Opposing various legislative efforts to relocate supply and logistics chains Opposing various legislative and executive efforts to impose an international price index Supporting the SMART Act (S. 3752 and H.R. 6954)

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Supporting changes to Medicare Part D's coverage gap liability assignment and out-of-pocket cliff. Supporting changes to the America Invents Act to prevent double jeopardy of patent challenges under the inter partes review process. Supporting the Hatch Waxman Integrity Act (HR 990, S344). Opposing the Medicare Negotiations and Competitive Pricing Act (HR 1046). Generally supporting the proposed CMS Safe Harbor rule. Generally supporting the proposed United States Mexico Canada (USMCA) Trade Agreement. Opposing H.R. 3 legislation regarding health care costs Opposing the FDA's Proposed Rule regarding the importation of prescription drugs (Docket No. FDA-2019-N-5711) Supporting H.R. 5741, the "Strengthening Innovation in Medicare and Medicaid Act Supporting the CMS Notice of Benefit and Payment Parameters (NBPP) Proposed Rule (CMS-9944-P) Opposing a proposed White House Executive Order concerning the Buy America Act Opposing various legislative efforts to relocate supply and logistics chains Opposing various legislative efforts to impose an international price index Supporting the SMART Act (S. 3752 and H.R. 6954)

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Supporting changes to Medicare Part D's coverage gap liability assignment and out-of-pocket cliff. Supporting changes to the America Invents Act to prevent double jeopardy of patent challenges under the inter partes review process. Supporting the Hatch Waxman Integrity Act (HR 990, S344). Opposing the Medicare Negotiations and Competitive Pricing Act (HR 1046). Generally supporting the proposed CMS Safe Harbor rule. Opposing H.R. 3 legislation regarding health care costs Opposing the FDA's Proposed Rule regarding the importation of prescription drugs (Docket No. FDA-2019-N-5711) Supporting H.R. 5741, the "Strengthening Innovation in Medicare and Medicaid Act Supporting the CMS Notice of Benefit and Payment Parameters (NBPP) Proposed Rule (CMS-9944-P) Opposing a proposed White House Executive Order concerning the Buy America Act Opposing various legislative efforts to relocate supply and logistics chains Opposing various legislative and executive efforts to impose an international price index Supporting the SMART Act (S. 3752 and H.R. 6954) Supporting the DISARM Act (S. 1712 and H.R. 4100)

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Supporting changes to Medicare Part D's coverage gap liability assignment and out-of-pocket cliff. Supporting changes to the America Invents Act to prevent double jeopardy of patent challenges under the inter partes review process. Supporting the Hatch Waxman Integrity Act (HR 990, S344). Opposing the Medicare Negotiations and Competitive Pricing Act (HR 1046). Generally supporting the proposed CMS Safe Harbor rule. Generally supporting the proposed United States Mexico Canada (USMCA) Trade Agreement. Opposing H.R. 3 legislation regarding health care costs Opposing the FDA's Proposed Rule regarding the importation of prescription drugs (Docket No. FDA-2019-N-5711) Supporting H.R. 5741, the "Strengthening Innovation in Medicare and Medicaid Act Supporting the CMS Notice of Benefit and Payment Parameters (NBPP) Proposed Rule (CMS-9944-P) Opposing a proposed White House Executive Order concerning the Buy America Act

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Supporting changes to Medicare Part D's coverage gap liability assignment and out-of-pocket cliff. Supporting changes to the America Invents Act to prevent double jeopardy of patent challenges under the inter partes review process. Supporting the Hatch Waxman Integrity Act (HR 990, S344). Opposing the Medicare Negotiations and Competitive Pricing Act (HR 1046). Generally supporting the proposed CMS Safe Harbor rule. Generally supporting the proposed United States Mexico Canada (USMCA) Trade Agreement. Opposing H.R. 3 legislation regarding health care costs Opposing the FDA's Proposed Rule regarding the importation of prescription drugs (Docket No. FDA-2019-N-5711) Supporting H.R. 5741, the "Strengthening Innovation in Medicare and Medicaid Act Supporting the CMS Notice of Benefit and Payment Parameters (NBPP) Proposed Rule (CMS-9944-P) Opposing a proposed White House Executive Order concerning the Buy America Act

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Supporting changes to Medicare Part D's coverage gap liability assignment and out-of-pocket cliff. Supporting changes to the America Invents Act to prevent double jeopardy of patent challenges under the inter partes review process. Supporting the Hatch Waxman Integrity Act (HR 990, S344). Opposing the Medicare Negotiations and Competitive Pricing Act (HR 1046). Generally supporting the proposed CMS Safe Harbor rule. Generally supporting the proposed United States Mexico Canada (USMCA) Trade Agreement. Opposing H.R. 3 legislation regarding health care costs Opposing the FDA's Proposed Rule regarding the importation of prescription drugs (Docket No. FDA-2019-N-5711) Supporting H.R. 5741, the "Strengthening Innovation in Medicare and Medicaid Act Supporting the CMS Notice of Benefit and Payment Parameters (NBPP) Proposed Rule (CMS-9944-P) Opposing a proposed White House Executive Order concerning the Buy America Act Opposing various legislative efforts to relocate supply and logistics chains Opposing various legislative efforts to impose an international price index Supporting the SMART Act (S. 3752 and H.R. 6954)

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Supporting changes to Medicare Part D's coverage gap liability assignment and out-of-pocket cliff. Supporting changes to the America Invents Act to prevent double jeopardy of patent challenges under the inter partes review process. Supporting the Hatch Waxman Integrity Act (HR 990, S344). Opposing the Medicare Negotiations and Competitive Pricing Act (HR 1046). Generally supporting the proposed CMS Safe Harbor rule. Opposing H.R. 3 legislation regarding health care costs Opposing the FDA's Proposed Rule regarding the importation of prescription drugs (Docket No. FDA-2019-N-5711) Supporting H.R. 5741, the "Strengthening Innovation in Medicare and Medicaid Act Supporting the CMS Notice of Benefit and Payment Parameters (NBPP) Proposed Rule (CMS-9944-P) Opposing a proposed White House Executive Order concerning the Buy America Act Opposing various legislative efforts to relocate supply and logistics chains Opposing various legislative and executive efforts to impose an international price index Supporting the SMART Act (S. 3752 and H.R. 6954)

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Supporting changes to Medicare Part D's coverage gap liability assignment and out-of-pocket cliff. Supporting changes to the America Invents Act to prevent double jeopardy of patent challenges under the inter partes review process. Supporting the Hatch Waxman Integrity Act (HR 990, S344). Opposing the Medicare Negotiations and Competitive Pricing Act (HR 1046). Generally supporting the proposed CMS Safe Harbor rule. Opposing H.R. 3 legislation regarding health care costs Opposing the FDA's Proposed Rule regarding the importation of prescription drugs (Docket No. FDA-2019-N-5711) Supporting H.R. 5741, the "Strengthening Innovation in Medicare and Medicaid Act Supporting the CMS Notice of Benefit and Payment Parameters (NBPP) Proposed Rule (CMS-9944-P) Opposing a proposed White House Executive Order concerning the Buy America Act Opposing various legislative efforts to relocate supply and logistics chains Opposing various legislative and executive efforts to impose an international price index Supporting the SMART Act (S. 3752 and H.R. 6954) Supporting the DISARM Act (S. 1712 and H.R. 4100)

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Supporting changes to Medicare Part D's coverage gap liability assignment and out-of-pocket cliff. Supporting changes to the America Invents Act to prevent double jeopardy of patent challenges under the inter partes review process. Supporting the Hatch Waxman Integrity Act (HR 990, S344). Opposing the Medicare Negotiations and Competitive Pricing Act (HR 1046). Generally supporting the proposed CMS Safe Harbor rule. Opposing H.R. 3 legislation regarding health care costs Opposing the FDA's Proposed Rule regarding the importation of prescription drugs (Docket No. FDA-2019-N-5711) Supporting H.R. 5741, the "Strengthening Innovation in Medicare and Medicaid Act Supporting the CMS Notice of Benefit and Payment Parameters (NBPP) Proposed Rule (CMS-9944-P) Opposing a proposed White House Executive Order concerning the Buy America Act Opposing various legislative efforts to relocate supply and logistics chains Opposing various legislative and executive efforts to impose an international price index Supporting the SMART Act (S. 3752 and H.R. 6954) Supporting the DISARM Act (S. 1712 and H.R. 4100)

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Supporting changes to Medicare Part D's coverage gap liability assignment and out-of-pocket cliff. Supporting changes to the America Invents Act to prevent double jeopardy of patent challenges under the inter partes review process. Supporting the Hatch Waxman Integrity Act (HR 990, S344). Opposing the Medicare Negotiations and Competitive Pricing Act (HR 1046). Generally supporting the proposed CMS Safe Harbor rule. Generally supporting the proposed United States Mexico Canada (USMCA) Trade Agreement. Opposing H.R. 3 legislation regarding health care costs Opposing the FDA's Proposed Rule regarding the importation of prescription drugs (Docket No. FDA-2019-N-5711) Supporting H.R. 5741, the "Strengthening Innovation in Medicare and Medicaid Act Supporting the CMS Notice of Benefit and Payment Parameters (NBPP) Proposed Rule (CMS-9944-P) Opposing a proposed White House Executive Order concerning the Buy America Act Opposing various legislative efforts to relocate supply and logistics chains Opposing various legislative efforts to impose an international price index Supporting the SMART Act (S. 3752 and H.R. 6954)

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Supporting changes to Medicare Part D's coverage gap liability assignment and out-of-pocket cliff. Supporting changes to the America Invents Act to prevent double jeopardy of patent challenges under the inter partes review process. Supporting the Hatch Waxman Integrity Act (HR 990, S344). Opposing the Medicare Negotiations and Competitive Pricing Act (HR 1046). Generally supporting the proposed CMS Safe Harbor rule. Generally supporting the proposed United States Mexico Canada (USMCA) Trade Agreement. Opposing H.R. 3 legislation regarding health care costs Opposing the FDA's Proposed Rule regarding the importation of prescription drugs (Docket No. FDA-2019-N-5711) Supporting H.R. 5741, the "Strengthening Innovation in Medicare and Medicaid Act Supporting the CMS Notice of Benefit and Payment Parameters (NBPP) Proposed Rule (CMS-9944-P) Opposing a proposed White House Executive Order concerning the Buy America Act

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Supporting changes to Medicare Part D's coverage gap liability assignment and out-of-pocket cliff. Supporting changes to the America Invents Act to prevent double jeopardy of patent challenges under the inter partes review process. Supporting the Hatch Waxman Integrity Act (HR 990, S344). Opposing the Medicare Negotiations and Competitive Pricing Act (HR 1046). Generally supporting the proposed CMS Safe Harbor rule. Opposing H.R. 3 legislation regarding health care costs Opposing the FDA's Proposed Rule regarding the importation of prescription drugs (Docket No. FDA-2019-N-5711) Supporting H.R. 5741, the "Strengthening Innovation in Medicare and Medicaid Act Supporting the CMS Notice of Benefit and Payment Parameters (NBPP) Proposed Rule (CMS-9944-P) Opposing a proposed White House Executive Order concerning the Buy America Act Opposing various legislative efforts to relocate supply and logistics chains Opposing various legislative and executive efforts to impose an international price index Supporting the SMART Act (S. 3752 and H.R. 6954)

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Supporting changes to Medicare Part D's coverage gap liability assignment and out-of-pocket cliff. Supporting changes to the America Invents Act to prevent double jeopardy of patent challenges under the inter partes review process. Supporting the Hatch Waxman Integrity Act (HR 990, S344). Opposing the Medicare Negotiations and Competitive Pricing Act (HR 1046). Generally supporting the proposed CMS Safe Harbor rule. Opposing H.R. 3 legislation regarding health care costs Opposing the FDA's Proposed Rule regarding the importation of prescription drugs (Docket No. FDA-2019-N-5711) Supporting H.R. 5741, the "Strengthening Innovation in Medicare and Medicaid Act Supporting the CMS Notice of Benefit and Payment Parameters (NBPP) Proposed Rule (CMS-9944-P) Opposing a proposed White House Executive Order concerning the Buy America Act Opposing various legislative efforts to relocate supply and logistics chains Opposing various legislative and executive efforts to impose an international price index Supporting the SMART Act (S. 3752 and H.R. 6954) Supporting the DISARM Act (S. 1712 and H.R. 4100)

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Supporting changes to Medicare Part D's coverage gap liability assignment and out-of-pocket cliff. Supporting changes to the America Invents Act to prevent double jeopardy of patent challenges under the inter partes review process. Supporting the Hatch Waxman Integrity Act (HR 990, S344). Opposing the Medicare Negotiations and Competitive Pricing Act (HR 1046). Generally supporting the proposed CMS Safe Harbor rule. Opposing H.R. 3 legislation regarding health care costs Opposing the FDA's Proposed Rule regarding the importation of prescription drugs (Docket No. FDA-2019-N-5711) Supporting H.R. 5741, the "Strengthening Innovation in Medicare and Medicaid Act Supporting the CMS Notice of Benefit and Payment Parameters (NBPP) Proposed Rule (CMS-9944-P) Opposing a proposed White House Executive Order concerning the Buy America Act Opposing various legislative efforts to relocate supply and logistics chains Opposing various legislative and executive efforts to impose an international price index Supporting the SMART Act (S. 3752 and H.R. 6954) Supporting the DISARM Act (S. 1712 and H.R. 4100)

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Supporting changes to Medicare Part D's coverage gap liability assignment and out-of-pocket cliff. Supporting changes to the America Invents Act to prevent double jeopardy of patent challenges under the inter partes review process. Supporting the Hatch Waxman Integrity Act (HR 990, S344). Opposing the Medicare Negotiations and Competitive Pricing Act (HR 1046). Generally supporting the proposed CMS Safe Harbor rule. Opposing H.R. 3 legislation regarding health care costs Opposing the FDA's Proposed Rule regarding the importation of prescription drugs (Docket No. FDA-2019-N-5711) Supporting H.R. 5741, the "Strengthening Innovation in Medicare and Medicaid Act Supporting the CMS Notice of Benefit and Payment Parameters (NBPP) Proposed Rule (CMS-9944-P) Opposing a proposed White House Executive Order concerning the Buy America Act Opposing various legislative efforts to relocate supply and logistics chains Opposing various legislative and executive efforts to impose an international price index Supporting the SMART Act (S. 3752 and H.R. 6954)

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Supporting changes to Medicare Part D's coverage gap liability assignment and out-of-pocket cliff. Supporting changes to the America Invents Act to prevent double jeopardy of patent challenges under the inter partes review process. Supporting the Hatch Waxman Integrity Act (HR 990, S344). Opposing the Medicare Negotiations and Competitive Pricing Act (HR 1046). Generally supporting the proposed CMS Safe Harbor rule. Generally supporting the proposed United States Mexico Canada (USMCA) Trade Agreement. Opposing H.R. 3 legislation regarding health care costs Opposing the FDA's Proposed Rule regarding the importation of prescription drugs (Docket No. FDA-2019-N-5711) Supporting H.R. 5741, the "Strengthening Innovation in Medicare and Medicaid Act Supporting the CMS Notice of Benefit and Payment Parameters (NBPP) Proposed Rule (CMS-9944-P) Opposing a proposed White House Executive Order concerning the Buy America Act Opposing various legislative efforts to relocate supply and logistics chains Opposing various legislative efforts to impose an international price index Supporting the SMART Act (S. 3752 and H.R. 6954)

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Supporting changes to Medicare Part D's coverage gap liability assignment and out-of-pocket cliff. Supporting changes to the America Invents Act to prevent double jeopardy of patent challenges under the inter partes review process. Supporting the Hatch Waxman Integrity Act (HR 990, S344). Opposing the Medicare Negotiations and Competitive Pricing Act (HR 1046). Generally supporting the proposed CMS Safe Harbor rule. Opposing H.R. 3 legislation regarding health care costs Opposing the FDA's Proposed Rule regarding the importation of prescription drugs (Docket No. FDA-2019-N-5711) Supporting H.R. 5741, the "Strengthening Innovation in Medicare and Medicaid Act Supporting the CMS Notice of Benefit and Payment Parameters (NBPP) Proposed Rule (CMS-9944-P) Opposing a proposed White House Executive Order concerning the Buy America Act Opposing various legislative efforts to relocate supply and logistics chains Opposing various legislative and executive efforts to impose an international price index Supporting the SMART Act (S. 3752 and H.R. 6954) Supporting the DISARM Act (S. 1712 and H.R. 4100)

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Supporting changes to Medicare Part D's coverage gap liability assignment and out-of-pocket cliff. Supporting changes to the America Invents Act to prevent double jeopardy of patent challenges under the inter partes review process. Supporting the Hatch Waxman Integrity Act (HR 990, S344). Opposing the Medicare Negotiations and Competitive Pricing Act (HR 1046). Generally supporting the proposed CMS Safe Harbor rule. Opposing H.R. 3 legislation regarding health care costs Opposing the FDA's Proposed Rule regarding the importation of prescription drugs (Docket No. FDA-2019-N-5711) Supporting H.R. 5741, the "Strengthening Innovation in Medicare and Medicaid Act Supporting the CMS Notice of Benefit and Payment Parameters (NBPP) Proposed Rule (CMS-9944-P) Opposing a proposed White House Executive Order concerning the Buy America Act Opposing various legislative efforts to relocate supply and logistics chains Opposing various legislative and executive efforts to impose an international price index Supporting the SMART Act (S. 3752 and H.R. 6954)

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Supporting changes to Medicare Part D's coverage gap liability assignment and out-of-pocket cliff. Supporting changes to the America Invents Act to prevent double jeopardy of patent challenges under the inter partes review process. Supporting the Hatch Waxman Integrity Act (HR 990, S344). Opposing the Medicare Negotiations and Competitive Pricing Act (HR 1046). Generally supporting the proposed CMS Safe Harbor rule. Generally supporting the proposed United States Mexico Canada (USMCA) Trade Agreement. Opposing H.R. 3 legislation regarding health care costs Opposing the FDA's Proposed Rule regarding the importation of prescription drugs (Docket No. FDA-2019-N-5711) Supporting H.R. 5741, the "Strengthening Innovation in Medicare and Medicaid Act Supporting the CMS Notice of Benefit and Payment Parameters (NBPP) Proposed Rule (CMS-9944-P) Opposing a proposed White House Executive Order concerning the Buy America Act Opposing various legislative efforts to relocate supply and logistics chains Opposing various legislative efforts to impose an international price index Supporting the SMART Act (S. 3752 and H.R. 6954)

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Supporting changes to Medicare Part D's coverage gap liability assignment and out-of-pocket cliff. Supporting changes to the America Invents Act to prevent double jeopardy of patent challenges under the inter partes review process. Supporting the Hatch Waxman Integrity Act (HR 990, S344). Opposing the Medicare Negotiations and Competitive Pricing Act (HR 1046). Generally supporting the proposed CMS Safe Harbor rule. Generally supporting the proposed United States Mexico Canada (USMCA) Trade Agreement. Opposing H.R. 3 legislation regarding health care costs Opposing the FDA's Proposed Rule regarding the importation of prescription drugs (Docket No. FDA-2019-N-5711) Supporting H.R. 5741, the "Strengthening Innovation in Medicare and Medicaid Act Supporting the CMS Notice of Benefit and Payment Parameters (NBPP) Proposed Rule (CMS-9944-P) Opposing a proposed White House Executive Order concerning the Buy America Act

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Supporting changes to Medicare Part D's coverage gap liability assignment and out-of-pocket cliff. Supporting changes to the America Invents Act to prevent double jeopardy of patent challenges under the inter partes review process. Supporting the Hatch Waxman Integrity Act (HR 990, S344). Opposing the Medicare Negotiations and Competitive Pricing Act (HR 1046). Generally supporting the proposed CMS Safe Harbor rule. Opposing H.R. 3 legislation regarding health care costs Opposing the FDA's Proposed Rule regarding the importation of prescription drugs (Docket No. FDA-2019-N-5711) Supporting H.R. 5741, the "Strengthening Innovation in Medicare and Medicaid Act Supporting the CMS Notice of Benefit and Payment Parameters (NBPP) Proposed Rule (CMS-9944-P) Opposing a proposed White House Executive Order concerning the Buy America Act Opposing various legislative efforts to relocate supply and logistics chains Opposing various legislative and executive efforts to impose an international price index Supporting the SMART Act (S. 3752 and H.R. 6954) Supporting the DISARM Act (S. 1712 and H.R. 4100)

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Supporting changes to Medicare Part D's coverage gap liability assignment and out-of-pocket cliff. Supporting changes to the America Invents Act to prevent double jeopardy of patent challenges under the inter partes review process. Supporting the Hatch Waxman Integrity Act (HR 990, S344). Opposing the Medicare Negotiations and Competitive Pricing Act (HR 1046). Generally supporting the proposed CMS Safe Harbor rule. Generally supporting the proposed United States Mexico Canada (USMCA) Trade Agreement. Opposing H.R. 3 legislation regarding health care costs Opposing the FDA's Proposed Rule regarding the importation of prescription drugs (Docket No. FDA-2019-N-5711) Supporting H.R. 5741, the "Strengthening Innovation in Medicare and Medicaid Act Supporting the CMS Notice of Benefit and Payment Parameters (NBPP) Proposed Rule (CMS-9944-P) Opposing a proposed White House Executive Order concerning the Buy America Act Opposing various legislative efforts to relocate supply and logistics chains Opposing various legislative efforts to impose an international price index Supporting the SMART Act (S. 3752 and H.R. 6954)

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Supporting changes to Medicare Part D's coverage gap liability assignment and out-of-pocket cliff. Supporting changes to the America Invents Act to prevent double jeopardy of patent challenges under the inter partes review process. Supporting the Hatch Waxman Integrity Act (HR 990, S344). Opposing the Medicare Negotiations and Competitive Pricing Act (HR 1046). Generally supporting the proposed CMS Safe Harbor rule. Opposing H.R. 3 legislation regarding health care costs Opposing the FDA's Proposed Rule regarding the importation of prescription drugs (Docket No. FDA-2019-N-5711) Supporting H.R. 5741, the "Strengthening Innovation in Medicare and Medicaid Act Supporting the CMS Notice of Benefit and Payment Parameters (NBPP) Proposed Rule (CMS-9944-P) Opposing a proposed White House Executive Order concerning the Buy America Act Opposing various legislative efforts to relocate supply and logistics chains Opposing various legislative and executive efforts to impose an international price index Supporting the SMART Act (S. 3752 and H.R. 6954)

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Supporting changes to Medicare Part D's coverage gap liability assignment and out-of-pocket cliff. Supporting changes to the America Invents Act to prevent double jeopardy of patent challenges under the inter partes review process. Supporting the Hatch Waxman Integrity Act (HR 990, S344). Opposing the Medicare Negotiations and Competitive Pricing Act (HR 1046). Generally supporting the proposed CMS Safe Harbor rule. Generally supporting the proposed United States Mexico Canada (USMCA) Trade Agreement. Opposing H.R. 3 legislation regarding health care costs Opposing the FDA's Proposed Rule regarding the importation of prescription drugs (Docket No. FDA-2019-N-5711) Supporting H.R. 5741, the "Strengthening Innovation in Medicare and Medicaid Act Supporting the CMS Notice of Benefit and Payment Parameters (NBPP) Proposed Rule (CMS-9944-P) Opposing a proposed White House Executive Order concerning the Buy America Act

Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Supporting changes to Medicare Part D's coverage gap liability assignment and out-of-pocket cliff. Supporting changes to the America Invents Act to prevent double jeopardy of patent challenges under the inter partes review process. Supporting the Hatch Waxman Integrity Act (HR 990, S344). Opposing the Medicare Negotiations and Competitive Pricing Act (HR 1046). Generally supporting the proposed CMS Safe Harbor rule. Opposing H.R. 3 legislation regarding health care costs Opposing the FDA's Proposed Rule regarding the importation of prescription drugs (Docket No. FDA-2019-N-5711) Supporting H.R. 5741, the "Strengthening Innovation in Medicare and Medicaid Act Supporting the CMS Notice of Benefit and Payment Parameters (NBPP) Proposed Rule (CMS-9944-P) Opposing a proposed White House Executive Order concerning the Buy America Act Opposing various legislative efforts to relocate supply and logistics chains Opposing various legislative and executive efforts to impose an international price index Supporting the SMART Act (S. 3752 and H.R. 6954) Supporting the DISARM Act (S. 1712 and H.R. 4100)